Frontiers in Public Health (Jun 2023)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult

  • Thundon Ngamprasertchai,
  • Chayanis Kositamongkol,
  • Saranath Lawpoolsri,
  • Pinyo Rattanaumpawan,
  • Viravarn Luvira,
  • Piriyaporn Chongtrakool,
  • Jaranit Kaewkungwal,
  • Kulkanya Chokephaibulkit,
  • Kulkanya Chokephaibulkit,
  • Pochamana Phisalprapa

DOI
https://doi.org/10.3389/fpubh.2023.1071117
Journal volume & issue
Vol. 11

Abstract

Read online

IntroductionThis study aims to assess the economic impact of introducing the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to Thai older adult aged ≥ 65 years who are healthy or with chronic health conditions and immunocompromised conditions from a societal perspective in order to introduce the vaccine to Thailand’s National Immunization Program for the older adult.MethodsA Markov model was adopted to simulate the natural history and economic outcomes of invasive pneumococcal diseases using updated published sources and Thai databases. We reported analyses as incremental cost-effectiveness ratios (ICER) in USD per quality-adjusted life year (QALY) gained. In addition, sensitivity analyses and budget impact analyses were conducted.ResultsThe base-case analysis of all interventions (no vaccinations [current standard of care in Thailand], PPSV23, and PCV13) showed that PPSV23 was extendedly dominated by PCV13. Among healthy individuals or those with chronic health conditions, ICER for PCV13 was 233.63 USD/QALY; meanwhile, among individuals with immunocompromised conditions, ICER for PCV13 was 627.24 USD/QALY. PCV13 are economical vaccine for all older adult Thai individuals when compared to all interventions.ConclusionsIn the context of Thailand, PCV13 is recommended as the best buy and should be primarily prioritized when both costs and benefits are considered. Also, this model will be beneficial to the two-next generation pneumococcal vaccines implementation in Thailand.

Keywords